Tarveda Therapeutics to Present at Raymond James Life Sciences and MedTech Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda
Therapeutics®, Inc.
, a clinical stage biopharmaceutical company
discovering and developing a new class of potent and selective precision
oncology medicines for the treatment of patients with a wide range of
solid tumor malignancies, today announced that Drew Fromkin, President
and Chief Executive Officer, will present at the Raymond James Life
Sciences and MedTech Conference occurring June 18-19, 2019 in New York
City. Tarveda presentation details:

Date: Tuesday, June 18, 2019
Time: 8:00am Eastern Time
Location:
Lotte New York Palace, New York, NY

About Tarveda Therapeutics®, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company that
is developing and discovering a new class of potent and selective
precision oncology medicines for the treatment of patients with solid
tumor malignancies. We are developing our proprietary Pentarin®
miniature conjugates to enhance the effectiveness of promising
anti-cancer payloads by selectively binding them to desired tumor
targets where they accumulate. http://www.tarvedatx.com/

Contacts

Amanda Houlihan
MacDougall
781 235 3060
[email protected]

error: Content is protected !!